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1. Quality control
Quality control refers to the process of quality evaluation that focuses on the internal meas‐
urement of the quality of a process, institution, product, service, or other. Often used inter‐
changeably with quality management and quality assurance [1-3].
2. Drug quality control
Quality Assurance plays a very important role in making sure that the GMP standards are
met and products comply with the international quality standards. The main functions car‐
ried out by drug quality control are:
• Approval of raw materials
• Monitoring of manufacturing processes
• Approval of finished products
• Documentation of technical information
• Implementation of cGMP
Manufacturing processes are monitored and controlled by testing of raw materials, in-process
parameters. Final active pharmaceutical ingredients and dosage forms are tested for specified
parameters before release. Analytical testing is carried out with highly sophisticated instru‐
ments: viz. HPLC, GC, IR, UV spectrophotometer mettler titrators, particle size analyzer etc.
© 2012 Mennickent et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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All the analytical test procedures and manufacturing procedures are well documented and
revision is undertaken as per specified protocol. Analytical methods are validated to give
the reproducible results. Stability study as per stability protocol is considered to be very im‐
portant area of Quality Assurance.
Automated systems are becoming increasingly important tools for appropriate monitoring
and controlling of the pharmaceutical packaging process. Solutions for comprehensive qual‐
ity assurance or production data acquisition and evaluation are just as important as applica‐
tions that meet the legislative requirements of different countries in terms of serial
numbering and the unique marking of products.
Quality control involves many phases, such as sample collection, measuring, analysis of re‐
sults, and the approval/rejection of the batch. Nonetheless, the most important thing is the
continuity and systematization of the quality control.
Effective process validation contributes significantly to assuring drug quality. The basic
principle of quality assurance is that a drug should be produced that is fit for its intended
use. This principle incorporates the understanding that the following conditions exist: Qual‐
ity, safety, and efficacy are designed or built into the product.
Quality cannot be adequately assured merely by in-process and finished-product inspec‐
tion or testing.
Process validation is defined as the collection and evaluation of data, from the process de‐
sign stage through commercial production, which establishes scientific evidence that a proc‐
ess is capable of consistently delivering quality product. Process validation involves a series
of activities taking place over the lifecycle of the product and process. Usually, process vali‐
dation includes three stages:
• Process Design: The commercial manufacturing process is defined during this stage based
on knowledge gained through development and scale-up activities.
• Process Qualification: During this stage, the process design is evaluated to determine if
the process is capable of reproducible commercial manufacturing.
• Process Verification: Ongoing assurance is gained during routine production that the
process remains in a state of control [1-3].
3. New approaches in drug quality control
3.1. Matrices
3.1.1. Residue analysis of pharmaceuticals in the aquatic environment
Residue analysis of pharmaceuticals in the aquatic environment has attracted considerable
interest during the last few years.
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Traces of such compounds have been detected in surface water samples from all countries
where pharmaceuticals are widely in use.
Pharmaceutically active compounds have captured the attention of the scientific community
because such pollutants result not primarily from manufacturing but from widespread, con‐
tinual use in human and veterinary clinical practice. The biological activity of these com‐
pounds can lead to adverse effects in aquatic ecosystems and potentially have an impact on
drinking-water supplies [4].
In the human body, pharmaceuticals can be transformed to one or more metabolites and ex‐
creted as a mixture of parent compound and metabolites, in which the parent compound is
often the minor component. However, some drugs are poorly metabolized and are excreted
unchanged. The degree of metabolism depends on a number of parameters, including age,
gender and ethnicity, the constitution of the patient and the time of administration. Drug-
drug interactions caused by enzyme induction or inhibition, as well as enhanced metabo‐
lism due to previous exposure, can also influence the pharmacokinetics of drugs [5].
Both the parent compound and the metabolites enter the aquatic environment once they are
excreted from the human body. Monitoring studies in the environment have demonstrated
the discharge of pharmaceuticals and their metabolites through municipal wastewater-treat‐
ment plants (WWTPs). Although unchanged drugs can undergo biochemical transforma‐
tions during sewage treatment, some studies indicate that the absence of pharmaceutical
compounds in treated water does not necessarily imply their complete removal. In most in‐
stances, human drugs are metabolized in the body to more polar compounds that are more
likely to pass through the WWTP. In some cases, pharmaceuticals and their human metabo‐
lites can be microbially degraded in the activated sludge treatment.
Knowledge of the formation of stable metabolites in WWTPs is also important in order to
understand the environmental fate of the parent compound. Once in the environment, these
compounds can be transported and distributed in rivers, streams, and possibly further bio‐
degraded. For most pharmaceuticals and their biotransformation products, these pathways
in the aquatic environment are largely unknown, and investigations into their occurrence in
environmental compartments are still rare.
Studies have been carried out to investigate their fate not only in surface waters, but also in
sediment and soil environments. By nature, most pharmaceuticals are designed to be at least
moderately water-soluble and to possess half-lives in the human body in the range of hours.
Because  human and  microbial  degradates  will  generally  coexist  with  their  parent  com‐
pounds in the environment, indicators that summarize all the information on parent substan‐
ces and degradates would be important instruments for decision-making and assessment [6].
Progress in instrumental analytical chemistry has resulted in the availability of methods that
allow a monitoring of these pollutants at ng levels.
Improvements in detection limits over the past years have mainly been due to sophisticated
mass spectrometric detection techniques. Furthermore, robust sample preparation and pre-
concentration protocols have contributed significantly to the achievements observed so far.
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Nowadays it is a well-established fact that pharmaceutical drugs used during medical treat‐
ment may partly be excreted in an un-metabolized form, enter municipal sewage systems,
and can even survive the passage through the sewage treatment plant. Therefore, sewage
treatment plant effluents are the major source for introduction of pharmaceuticals into the
aquatic environment. Furthermore, pharmaceuticals employed in veterinary medicine may
be introduced into soil (and eventually into water) via manure, or may find a direct way in‐
to the aquatic system when used in fish farms.
Unfortunately, the consequences of continuous presence of low concentrations of pharma‐
ceuticals for the ecosystem are still not fully known.
In many cases, the analytical procedures for residue analysis of pharmaceutical drugs nowa‐
days available includes a pre-concentration and clean-up step by solid-phase extraction or
related techniques, followed by chromatography in combination with mass spectrometry
(MS) as detector.
Although GC–MS may still be the perfect technique for certain classes of pharmaceuticals,
high-performance liquid chromatography (HPLC) hyphenated with atmospheric pressure
ionization-MS has established itself as the better choice for simultaneous determination of
pharmaceuticals of widely differing structures.
The concentration levels of pharmaceuticals found in environmental water samples are gen‐
erally too low to allow a direct injection into a chromatographic system. Therefore, efficient
pre-concentration steps are necessary which should also result in some sample clean-up.
One of the most widely used sample treatment technique for residue analysis of pharma‐
ceuticals in water is the extraction of the analytes by means of a solid sorbent.
This extraction procedure can be based on multiple equilibria between the liquid phase and
the sorbent filled into a small cartridge (solid-phase extraction, SPE), or on a single equilibri‐
um (sorptive extraction) [7-23].
3.1.1.1. Solid-phase extraction
Pharmaceuticals of adequate hydrophobicity can easily be pre-concentrated using any re‐
versed-phase material such as alkyl-modified silica or polymer-based materials. Deprotona‐
tion of acidic compounds and protonation of basic compounds should be suppressed to
ensure sufficient hydrophobicity of the analytes. Therefore, acidic pharmaceuticals should
be pre-concentrated under acidic conditions, whereas basic analytes should be pre-concen‐
trated at an alkaline pH. Alternatively, mixed-mode SPE materials can be used which exhib‐
it both reversed-phase and cation-exchange properties due to the presence of sulfonic acid
groups on the hydrophobic surface of the particles. Using acidified sample solutions, acidic
and neutral analytes would be extracted by hydrophobic interactions, whereas protonated
basic analytes would interact via ion exchange mechanisms.
A recent review has summarized new SPE materials that can improve the recoveries for po‐
lar analytes. These materials are mainly polymeric sorbents that improve the retention of po‐
lar compounds either by novel functional groups in the polymeric structure (resulting in a
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hydrophilic–hydrophobic balance material) or by considerably increased surface area. Some
of these new materials have turned out to be well suited for multi-class analysis of pharma‐
ceuticals in water samples. Nowadays, one of the most widely used sorbent is a copolymer
of divinylbenzene and vinylpyrrolidone [7-23].
3.1.1.2. Sorptive extraction
Sorptive extraction based on a single partitioning equilibrium of analytes between the aque‐
ous sample and a solid sorbent includes solid-phase microextraction (SPME), stir-bar sorp‐
tive extraction (SBSE), and several related variants. Originally, these techniques were based
on polydimethylsiloxane (PDMS) as material for trapping trace analytes from a water sam‐
ple due to partitioning between the aqueous matrix and the PDMS phase. Besides PDMS,
some alternative sorptive materials have become commercially available recently, such as
polyacrylates, copolymers of PDMS with divinylbenzene, copolymers of polyethylene glycol
with divinylbenzene, and mixtures of carboxen (an inorganic adsorbent) with PDMS or di‐
vinylbenzene [7-23].
3.1.1.3. Sample pre-concentration procedures for sediment and sludge samples
Extraction of pharmaceuticals from sediment and sludge is generally done by blending the
sample with an organic solvent or with mixtures of aqueous buffers and organic solvents.
Ultrasonication is frequently applied to assist the extraction process.
Additional clean-up steps for the extract may be necessary employing SPE or liquid–liq‐
uid extraction. Somewhat more advanced procedures are based on pressurized liquid ex‐
traction  (accelerated  solvent  extraction)  which  may  need  less  time  and  less  solvent
consumption [7-23].
3.1.1.4. Derivatization of the compounds
Various groups of pharmaceuticals can be derivatized to make them suited for GC analysis.
Typical derivatization reagents for acidic pharmaceuticals include pentafluorobenzylbro‐
mide, methyl chloromethanoate, methanol/BF3, or tetrabutylammonium salts (for derivati‐
zation during injection). Phenazone-type drugs have been derivatized by silylation using N-
tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA). Silylation procedures are
also commonly used for synthetic estrogens [7-23].
3.2.1.Some latest researches in this area
3.2.1.1. Pharmaceuticals in the aquatic environment: a critical review of the evidence for health effects
in fish
The authors review the current data on the presence and reported biological effects in fish of
some of the most commonly detected pharmaceuticals in the aquatic environment; namely
nonsteroidal anti-inflammatory drugs (NSAIDs), fibrates, beta-blockers, selective serotonin
New Approachs in Drug Quality Control: Matrices and Chemometrics
http://dx.doi.org/10.5772/50825
219
reuptake inhibitors (SSRIs), azoles, and antibiotics. Reported biological effects in fish in the
laboratory have often been shown to be in accordance with known effects of pharmaceuti‐
cals in mammals. Water concentrations at which such effects have been reported, however,
are generally, between microg L(-1) and mg L(-1), typically at least 1 order of magnitude
higher than concentrations normally found in surface waters (ng L(-1)). There are exceptions
to this, however, as for the case of synthetic oestrogens, which can induce biological effects
in the low ng L(-1) range. Although generally effect levels for pharmaceuticals are higher
than those found in the environment, the risks to wild fish populations have not been thor‐
oughly characterised, and there has been a lack of consideration given to the likely chronic
nature of the exposures, or the potential for mixture effects. As global consumption of phar‐
maceuticals rises, an inevitable consequence is an increased level of contamination of sur‐
face and ground waters with these biologically active drugs, and thus in turn a greater
potential for adverse effects in aquatic wildlife [24].
3.1.1.2. Human Pharmaceuticals, Hormones and Fragrances: The Challenge of Micropollutants in
Urban Water Management
The observed concentrations of pharmaceuticals and personal care products (PPCPs) in raw
wastewater confirm that municipal wastewater represents the main disposal pathway for
the PPCPs consumed in households, hospitals and industry. In sewage treatment plant ef‐
fluents most PPCPs are still present, since many of these polar and persistent compounds
are being removed only partially or, in some cases, not at all. Treated wastewater therefore
represents an important point source for PPCPs into the environment. After passing a sew‐
age treatment plant the treated wastewater is mostly discharged into rivers and streams or
sometimes used to irrigate fields. If drinking water is produced using resources containing a
substantial proportion of treated wastewater (e.g. from river water downstream of commun‐
ities) the water cycle is closed and indirect potable reuse occurs. Human Pharmaceuticals,
Hormones and Fragrances provides an overview of the occurrence, analytics, removal and
environmental risk of pharmaceuticals and personal care products in wastewater, surface
water and drinking water. [25].
3.2.1.2. Factors affecting the concentrations of pharmaceuticals released to the aquatic environment
Although recent research has demonstrated that pharmaceuticals are widely distributed in
the aquatic environment, it is difficult to assess the threat that they
pose to drinking water supplies or their rate of attenuation in natural systems without an
adequate understanding of the sources of contamination. To identify pharmaceutical com‐
pounds of significance to water supplies in the United States, the authors have reviewed
available data on the use of prescription drugs. Results of our analysis indicate that approxi‐
mately 40 compounds could be present in municipal wastewater effluent at concentrations
above 1,000 ng/L and at least 120 compounds could be present at concentrations above 1
ng/L. Important classes of prescription drugs include analgesics, beta-blockers, and antibiot‐
ics. Analysis of a group of the most commonly used pharmaceuticals in the United States
indicates that they are ubiquitous in wastewater effluents. Authors have detected concentra‐
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tions ranging from approximately 10- 3,000 ng/L for high use pharmaceuticals such as beta‐
blockers (e.g., metoprolol, propranolol) and acidic drugs (e.g., gemfibrozil, ibuprofen). The
concentration of pharmaceuticals in effluent from conventional wastewater treatment plants
is similar. Advanced wastewater treatment plants equipped with reverse osmosis systems
reduce concentrations of pharmaceuticals below detection limits. In addition to removal
during biological wastewater treatment, pharmaceuticals also are attenuated in engineered
natural systems (i.e., treatment wetlands, ground water infiltration basins). Preliminary evi‐
dence suggests limited removal of pharmaceuticals in engineered treatment wetlands and
nearly complete removal of pharmaceuticals during ground water infiltration [26].
3.2.1.3. A preliminary ecotoxicity study of pharmaceuticals in the marine environment
Environmental fates and effects of pharmaceuticals in the aquatic environment have been
the focus of recent research in environmental ecotoxicology. Worldwide studies of common
over-the-counter pharmaceuticals have reported detectable levels in the aquatic environ‐
ment, but there are few studies examining impacts on marine habitats. These drugs can af‐
fect the functions of various vertebrates and invertebrates. The stability of two
pharmaceuticals, cyclizine (CYC) and prochlorperazine (PCZ), in seawater was examined
under light and dark conditions, as well as the toxicity of these compounds to larvae of the
barnacle Balanus amphitrite, which is a cosmopolitan marine organism found in most of the
world's oceans. CYC was very stable under all the tested conditions. On the other hand,
PCZ degraded in light but not in the dark, and was more stable in seawater than fresh wa‐
ter. For the barnacle larvae, the LC50 of prochlorperazine was 0.93 microg/mL and the LC50
for CYC was approximately 0.04 microg/mL [27].
3.2.1.4. Estrogenic activity of pharmaceuticals in the aquatic environment
In  the  last  years  pharmaceuticals  have  aroused  great  interest  as  environmental  pollu‐
tants for their toxic effects towards non target organisms. This study wants to draw atten‐
tion to a further adverse effect of drugs, the endocrine interference. The most representative
drugs of the widespread classes in environment were investigated. The YES-test and the
E-screen  assay  were  performed to  detect  the  capability  of  these  substances  to  bind  the
human estrogenic receptor alpha (hER alpha) in comparison with 17beta-estradiol. Out of
14  tested  pharmaceuticals,  9  were  positive  to  YES-assay  and  11  were  positive  to  E-
screen assay; in particular, Furosemide and the fibrates (Bezafibrate, Fenofibrate and Gem‐
fibrozil)  gave  the  maximal  estrogenic  response.  Tamoxifen  showed  its  dual  activity  as
agonist and antagonist of hER alpha [28].
3.2.1.5. Colloids as a sink for certain pharmaceuticals in the aquatic environment
The occurrence and fate of pharmaceuticals in the aquatic environment is recognized as one
of the emerging issues in environmental chemistry and as a matter of public concern. Exist‐
ing data tend to focus on the concentrations of pharmaceuticals in the aqueous phase, with
limited studies on their concentrations in particulate phase such as sediments. Furthermore,
current water quality monitoring does not differentiate between soluble and colloidal phas‐
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es in water samples, hindering our understanding of the bioavailability and bioaccumula‐
tion of pharmaceuticals in aquatic organisms. In this study, an investigation was conducted
into the concentrations and phase association (soluble, colloidal, suspended particulate mat‐
ter or SPM) of selected pharmaceuticals (propranolol, sulfamethoxazole, meberverine, thio‐
ridazine, carbamazepine, tamoxifen, indomethacine, diclofenac, and meclofenamic acid) in
river water, effluents from sewage treatment works (STW), and groundwater in the UK.
Colloids were isolated by cross-flow ultrafiltration (CFUF). Water samples were extracted
by solid-phase extraction (SPE), while SPM was extracted by microwave. All sample extracts
were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in the
multiple reaction monitoring.
Five compounds propranolol, sulfamethoxazole, carbamazepine, indomethacine, and diclo‐
fenac were detected in all  samples,  with carbamazepine showing the highest  concentra‐
tions in all phases. The highest concentrations of these compounds were detected in STW
effluents,  confirming STW as  a  key  source  of  these  compounds in  the  aquatic  environ‐
ments.  The calculation of  partition coefficients of  pharmaceuticals  between SPM and fil‐
trate,  between SPM and soluble phase,  and between colloids and soluble phase showed
that intrinsic partition coefficients are between 25% and 96%, and between 18% and 82%
higher  than  relevant  observed  partition  coefficients  values,  and  are  much  less  variable.
Secondly,  K  coc  values  are  3–4  orders  of  magnitude  greater  than  Kocint  values,  indicat‐
ing that aquatic colloids are substantially more powerful sorbents for accumulating phar‐
maceuticals  than  sediments.  Furthermore,  mass  balance  calculations  of  pharmaceutical
concentrations demonstrate that between 23% and 70% of propranolol, 17–62% of sulfame‐
thoxazole,  7–58% of  carbamazepine,  19–84% of  indomethacine,  and 9–74% of  diclofenac
are present in the colloidal phase.
The results provide direct evidence that sorption to colloids provides an important sink for
the pharmaceuticals in the aquatic environment. Such strong pharmaceutical/colloid interac‐
tions may provide a long-term storage of pharmaceuticals, hence, increasing their persis‐
tence while reducing their bioavailability in the environment.
Recommendations and perspectives from this study:
Pharmaceutical compounds have been detected not only in the aqueous phase but also in
suspended particles; it is important, therefore, to have a holistic approach in future envi‐
ronmental fate investigation of pharmaceuticals. For example, more research is needed to
assess the storage and long-term record of pharmaceutical residues in aquatic sediments
by which benthic organisms will  be most affected. Aquatic colloids have been shown to
account for the accumulation of major fractions of total pharmaceutical concentrations in
the  aquatic  environment,  demonstrating  unequivocally  the  importance  of  aquatic  col‐
loids  as  a  sink  for  such  residues  in  the  aquatic  systems.  As  aquatic  colloids  are  abun‐
dant,  ubiquitous,  and  highly  powerful  sorbents,  they  are  expected  to  influence  the
bioavailability  and bioaccumulation of  such chemicals  by aquatic  organisms.  It  is  there‐
fore critical  for colloids to be incorporated into water quality models for prediction and
risk assessment purposes [29].
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4. Chemometrics
Chemometrics is the science of extracting information from chemical systems by data-driven
means. It is a highly interfacial discipline, using methods frequently employed in core data-
analytic disciplines such as multivariate statistics, applied mathematics, and computer sci‐
ence, in order to address problems in chemistry, biochemistry, medicine, biology and
chemical engineering.
Chemometrics is applied to solve both descriptive and predictive problems in experimental
life sciences, especially in chemistry. In descriptive applications, properties of chemical sys‐
tems are modeled with the intent of learning the underlying relationships and structure of
the system (i.e., model understanding and identification). In predictive applications, proper‐
ties of chemical systems are modeled with the intent of predicting new properties or behav‐
ior of interest. In both cases, the datasets can be small but are often very large and highly
complex, involving hundreds to thousands of variables, and hundreds to thousands of cases
or observations.
Chemometric techniques are particularly heavily used in analytical chemistry and metabolo‐
mics, and the development of improved chemometric methods of analysis also continues to
advance the state of the art in analytical instrumentation and methodology. It is an applica‐
tion driven discipline, and thus while the standard chemometric methodologies are very
widely used industrially, academic groups are dedicated to the continued development of
chemometric theory, method and application development [30-33].
Author details
Sigrid Mennickent1*, M. de Diego1, B. Schulz1, M.  Vega2 and C. G. Godoy1
*Address all correspondence to: smennick@udec.cl
1 Department of Pharmacy, Faculty of Pharmacy, University of Concepción, Concepción,,
Chile
2 Department of Bromatology, Nutrition and Dietetic, Faculty of Pharmacy, University of
Concepción, Concepción, , Chile
References
[1] USP (1999). The United States Pharmacopeia/ The National Formulary (USP 24/NF
19), United States Pharmacopeial Convection, Inc., Rockville
[2] ICH. (2003). The Sixth ICH International Conference on Armonization of Technical Re‐
quirements for Registration of Pharmaceuticals for Human Use, Osaka,.
New Approachs in Drug Quality Control: Matrices and Chemometrics
http://dx.doi.org/10.5772/50825
223
[3] Buchberger, W. W. (2007). Analytica Chimica Acta, 593, 129-139.
[4] Jones, O., Lester, J. N., & Voulvoulis, N. (2005). Trends in Biotechonology, 23(4),
163-167.
[5] Lemmer, B. (1996). Chronopharmacology- Cellular and Biochemical Interactions. Bir‐
khäuser,, New York, USA.
[6] Boxall, A., Fenner, K., Kolpin, D. W., & Maund, S. (2004). Environ. Sci. Technol., 38,
369A.
[7] Moldovan, Z. (2006). Chemosphere, 64, 1808.
[8] Cunningham, V. L., Buzby, M., Hutchinson, T., Mastrocco, F., Parke, N., & Roden, N.
(2006). Env. Sci. Technol, 40, 3457.
[9] Fent, K., Weston, A. A., & Caminada, D. (2006). Aquatic Toxicol, 76, 122.
[10] Crane, M., Watts, C., & Boucard, T. (2006). Sci. Tot. Environ, 367, 23.
[11] Hernando, M. D., Mezcua, M., Fernandez-Alba, A. R., & Barcelo, D. (2006). Talanta,
69, 334.
[12] Benito-Peña, E., Partal-Rodera, A. I., Leon-Gonzalez, M. E., & Moreno-Bondi, M. C.
(2006). Anal. Chim. Acta, 556, 415.
[13] Fontanals, N., Marce, R. M., & Borrull, F. (2005). Trends Anal. Chem ., 24, 394.
[14] Gomez, M. J., Petrovic, M., Fernandez-Alba, A. R., & Barcelo, D. (2006). J. Chromatogr.
A, 1114, 224.
[15] Gros, M., Petrovic, M., & Barcelo, D. (2006). Talanta, 70, 678.
[16] Petrovic, M., Gros, M., & Barcelo, D. (2006). J. Chromatogr. A, 1124, 68.
[17] Trenholm, R. A., Vanderford, B. J., Holady, J. C., Rexing, D. J., & Snyder, S. A. (2006).
Chemosphere, 65, 1990.
[18] Roberts, P. H., & Bersuder, P. (2006). J. Chromatogr. A, 1134, 143.
[19] Himmelsbach, M., Buchberger, W., & Klampfl, C. (2006). Electrophoresis, 27, 1220.
[20] Seitz, W., Weber, W. H., Jiang, J. Q., Lloyd, B. J., Maier, M., Maier, D., & Schulz, W.
(2006). Chemosphere, 64, 1318.
[21] Pozo, O. J., Guerrero, C., Sancho, J. V., Ibañez, M., Pitarch, E., Hogendoorn, E., &
Hernandez, F. (2006). J. Chromatogr. A, 1103, 83.
[22] Rodriguez-Mozaz, S., Lopez de Alda, D., & Barcelo, D. (2007). J. Chromatogr. A, 1152,
97.
[23] Quintana, J. B., Miro, M., Estela, J. M., & Cerda, V. (2006). Anal. Chem., 78, 2832.
[24] Corcoran, J., Winter, M. J., & Tyler, C. R. (2010). Crit, Rev. Toxicol, 40(4), 287-304.
Latest Research into Quality Control224
[25] Ternes, T. (2006). Human Pharmaceuticals, Hormones and Fragrances: The Chal‐
lenge of Micropollutants in Urban Water Management. Iwa Publishing.
[26] Sedlak, D., & Pinkston, K. (2011). Factors affecting the concentrations of pharmaceuticals
released to the aquatic environment, University of California.
[27] Choong, A. M., Teo, S. L., Leow, J. L., & Ho, P. C. (2006). J. Toxicol. Environ. Health A.,
69(21), 1959-1970.
[28] Isidori, M., Bellota, M., Cangiano, M., & Parrella, A. (2009). Environ. Int, 35(5),
826-829.
[29] Maskaoui, K., & Zhou, J. (2010). Environmental Science and Pollution Research, 17(4),
898-907.
[30] Verenitch, S. S., Lowe, C. J., & Mazumder, A. (2006). J. Chromatogr. A, 1116.
[31] Gemperline, P. J. (2006). Practical guide to chemometrics. 2nd Edition, CRC Press
10.1201/9781420018301
[32] Mark, H., & Workman, J. (2007). Chemometrics in spectroscopy. Academic Press-
Elsevier.
[33] Maeder, M., & Neuhold, Y. M. (2007). Practical Data Analysis in Chemistry. Elsevier.
New Approachs in Drug Quality Control: Matrices and Chemometrics
http://dx.doi.org/10.5772/50825
225

